Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 2Recurrence 1Postoperative Complications 1Peritoneal Neoplasms 1Neoplasm, Residual 1Gastric Adenocarcinoma 1Adrenocortical Carcinoma 1

Interventions

fludarabine 4Cyclophosphamide 4fludarabine phosphate 3Melphalan 3pembrolizumab 2obinutuzumab 2blinatumomab 2Rituximab 2Radiotherapy 2Lenalidomide 2Capecitabine 2Blood Specimen Collection 2trastuzumab deruxtecan 1tislelizumab 1tisagenlecleucel 1thymoglobulin 1tetrathiomolybdate 1talquetamab 1sacituzumab govitecan 1palbociclib 1nilotinib 1isatuximab 1avelumab 1atezolizumab 1acalabrutinib 1Whole-Body Irradiation 1Trastuzumab 1Sirolimus 1Neoadjuvant Therapy 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × Cytoreduction Surgical Procedures × 90 days × Clear all
NCT07567573 2026-05-05

retroESGO ov1

European Society of Gynaecological Oncology

Completed
11,383 enrolled
Gynecologic

Ovarian Neoplasms, Postoperative Complications, Recurrence, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡